Wissenschaftliche Publikationen Suche Suche Autor/in Forschungsgruppe Veröffentlichungsdatum Suchen Sortieren nach RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Reihenfolge AufsteigendAbsteigend Akalin, Altuna Dr. (3) Begay-Müller, Valerie Dr. (1) Birchmeier-Kohler, Carmen Prof. Dr. (1) Chekulaeva, Marina Dr. (3) Chen, Wei Prof. Dr. (1) Daniel, Peter Prof. Dr. (1) Daumke, Oliver Prof. Dr. (2) Franke, Vedran Dr. (3) Gotthardt, Michael Prof. Dr. (1) Haucke, Volker Professor (1) Heuser, Arnd Dr. (1) Hübner, Norbert Prof. Dr. (1) Janz, Martin Dr. (7) Kempa, Stefan Dr. (1) Kirchner, Marieluise Dr. (1) Kolesnichenko, Marina Dr. (1) Ku, Min-Chi Dr. (1) Landthaler, Markus Prof. Dr. (1) Lewin, Gary Prof. Dr. (1) Meyer, Irmtraud Margret Prof. Dr. (1) Müller, Thomas Dr. (1) Niendorf, Thoralf Prof. Dr. (1) Ohler, Uwe Prof. Dr. (3) Patone, Giannino Dr. (1) Poulet, James Prof. Dr. (1) Radke, Michael Dr. (1) Rajewsky, Nikolaus Prof. Dr. (2) Rocks, Oliver Dr. (1) Scheidereit, Claus Prof. Dr. (1) Schmitt, Clemens Prof. Dr. (1) Selbach, Matthias Prof. Dr. (13) Sommer, Christian (1) Specker, Edgar Dr. (1) von Kries, Jens Peter Dr. (1) Woehler, Andrew Dr. (2) Zauber, Henrik Dr. (1) (-) Lusatis, Simone (1) (-) Mathas, Stephan Dr. (9) (-) Wollert-Wulf, Brigitte (2) Bioinformatics and Omics Data Science (1) (-) Biologie maligner Lymphome (9) Genetik und Genomik von Herz- Kreislauferkrankungen (2) (-) Proteom Dynamik (1) Strukturbiologie Membran-assoziierter Prozesse (1) Tumorgenetik und zelluläre Stressantworten (1) 1999 (1) 2000 (1) 2001 (1) 2002 (5) 2003 (1) 2004 (2) 2005 (2) (-) 2006 (4) 2007 (3) 2008 (4) 2009 (3) 2010 (3) 2011 (4) 2012 (1) 2013 (3) 2014 (3) 2015 (5) 2016 (2) (-) 2017 (3) 2018 (1) (-) 2019 (2) 2020 (2) 2021 (3) 2022 (4) 2024 (1) 9 Ergebnisse: Active Filter: Lusatis, SimoneMathas, Stephan Dr.Wollert-Wulf, BrigitteBiologie maligner LymphomeProteom Dynamik200620172019 Sortieren: Treffgenauigkeit Neueste nach älteste Älteste nach neueste 01. Juli 2006 / Blood Chromosomal rearrangements involving the BCL3 locus are recurrent in classical Hodgkin and peripheral T-cell lymphoma J.I. Martin-Subero I. Wlodarska C. Bastard J.M. Picquenot J. Hoeppner M. Giefing W. Klapper R. Siebert S. Mathas S. Joos H. Stein B. Doerken 01. Februar 2006 / Nat Immunol Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma S. Mathas M. Janz F. Hummel M. Hummel B. Wollert-Wulf S. Lusatis I. Anagnostopoulos A. Lietz M. Sigvardsson F. Jundt K. Joehrens K. Bommert H. Stein B. Doerken 15. Mai 2006 / Cell Cycle Reprogramming of B lymphoid cells in human lymphoma pathogenesis M. Janz B. Doerken S. Mathas 15. März 2006 / Blood Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3) which promotes viability of Hodgkin/Reed-Sternberg cells M. Janz M. Hummel M. Truss B. Wollert-Wulf S. Mathas K. Joehrens C. Hagemeier K. Bommert H. Stein B. Doerken R.C. Bargou 05. Januar 2017 / Blood Pharmacological restoration and therapeutic targeting of the B-cell phenotype in classical Hodgkin's lymphoma J. Du M. Neuenschwander Y. Yu J.H.M. Däbritz N.R. Neuendorff K. Schleich A. Bittner M. Milanovic G. Beuster S. Radetzki E. Specker M. Reimann F. Rosenbauer S. Mathas P. Lohneis M. Hummel B. Dörken J.P. von Kries S. Lee C.A. Schmitt 01. Juni 2019 / Leukemia Global long terminal repeat activation participates in establishing the unique gene expression programme of classical Hodgkin lymphoma B. Edginton-White P. Cauchy S.A. Assi S. Hartmann A.G. Riggs S. Mathas P.N. Cockerill C. Bonifer 01. Dezember 2017 / Lancet Oncol Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group D.A. Eichenauer A. Plütschow S. Kreissl M. Sökler J.C. Hellmuth J. Meissner S. Mathas M.S. Topp K. Behringer W. Klapper G. Kuhnert M. Dietlein C. Kobe M. Fuchs V. Diehl A. Engert P. Borchmann 01. März 2017 / Leukemia Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma K.D. Wurster F. Hummel J. Richter M. Giefing S. Hartmann M.L. Hansmann S. Kreher K. Köchert D. Krappmann W. Klapper M. Hummel S.S. Wenzel G. Lenz M. Janz B. Dörken R. Siebert S. Mathas 28. März 2019 / Blood Autocrine LTA signaling drives NF-κB and JAK-STAT activity and myeloid gene expression in Hodgkin lymphoma L. von Hoff E. Kärgel V. Franke E. McShane K.W. Schulz-Beiss G. Patone N. Schleussner M. Kolesnichenko N. Hübner O. Daumke M. Selbach A. Akalin S. Mathas C. Scheidereit
01. Juli 2006 / Blood Chromosomal rearrangements involving the BCL3 locus are recurrent in classical Hodgkin and peripheral T-cell lymphoma J.I. Martin-Subero I. Wlodarska C. Bastard J.M. Picquenot J. Hoeppner M. Giefing W. Klapper R. Siebert S. Mathas S. Joos H. Stein B. Doerken
01. Februar 2006 / Nat Immunol Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma S. Mathas M. Janz F. Hummel M. Hummel B. Wollert-Wulf S. Lusatis I. Anagnostopoulos A. Lietz M. Sigvardsson F. Jundt K. Joehrens K. Bommert H. Stein B. Doerken
15. Mai 2006 / Cell Cycle Reprogramming of B lymphoid cells in human lymphoma pathogenesis M. Janz B. Doerken S. Mathas
15. März 2006 / Blood Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3) which promotes viability of Hodgkin/Reed-Sternberg cells M. Janz M. Hummel M. Truss B. Wollert-Wulf S. Mathas K. Joehrens C. Hagemeier K. Bommert H. Stein B. Doerken R.C. Bargou
05. Januar 2017 / Blood Pharmacological restoration and therapeutic targeting of the B-cell phenotype in classical Hodgkin's lymphoma J. Du M. Neuenschwander Y. Yu J.H.M. Däbritz N.R. Neuendorff K. Schleich A. Bittner M. Milanovic G. Beuster S. Radetzki E. Specker M. Reimann F. Rosenbauer S. Mathas P. Lohneis M. Hummel B. Dörken J.P. von Kries S. Lee C.A. Schmitt
01. Juni 2019 / Leukemia Global long terminal repeat activation participates in establishing the unique gene expression programme of classical Hodgkin lymphoma B. Edginton-White P. Cauchy S.A. Assi S. Hartmann A.G. Riggs S. Mathas P.N. Cockerill C. Bonifer
01. Dezember 2017 / Lancet Oncol Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group D.A. Eichenauer A. Plütschow S. Kreissl M. Sökler J.C. Hellmuth J. Meissner S. Mathas M.S. Topp K. Behringer W. Klapper G. Kuhnert M. Dietlein C. Kobe M. Fuchs V. Diehl A. Engert P. Borchmann
01. März 2017 / Leukemia Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma K.D. Wurster F. Hummel J. Richter M. Giefing S. Hartmann M.L. Hansmann S. Kreher K. Köchert D. Krappmann W. Klapper M. Hummel S.S. Wenzel G. Lenz M. Janz B. Dörken R. Siebert S. Mathas
28. März 2019 / Blood Autocrine LTA signaling drives NF-κB and JAK-STAT activity and myeloid gene expression in Hodgkin lymphoma L. von Hoff E. Kärgel V. Franke E. McShane K.W. Schulz-Beiss G. Patone N. Schleussner M. Kolesnichenko N. Hübner O. Daumke M. Selbach A. Akalin S. Mathas C. Scheidereit